This type of leukemia could be cured by experimental medicine

Leukemia is the most common form of cancer, according to the American Cancer Society. Cancer is in primitive blood cells. Leukemia is usually a cancer of the white blood cells, but some leukemias start in other types of blood cells.

According to the Mayo Clinic, this disease can affect the bone marrow and even the lymphatic system (responsible for transporting white blood cells).

It should be noted that the symptoms of this disease are multiple, depending on the quality of the blood cells that are affected by the condition and its severity.

Again, it seems that it can be cured, but only if it meets its own characteristics. This was discovered by a team of researchers from the MD Anderson Cancer Center of the University of Texas (United States).

Scientists have discovered that this can be cured at an advanced stage, after achieving this in 18 patients thanks to the administration of the experimental drug revumenib.once known as Sndx-5613, according to the Easter event I contemplate Augment-101, published in the journal Nature.

At the time, it was revealed that the total response among 60 patients was 53%, and the complete remission or complete remission with partial hematological recovery was 30%. In addition, 78% of patients achieved clearance of measurable residual disease.

“These results suggest that oral revumenib may be an effective targeted therapy for patients with acute leukemia caused by genetic alterations.. These response rates, especially residual disease clearance, are the highest we have seen with any monotherapy used for these subgroups of leukemia resistance,” explained study leader Ghayas Issa.

The trial included a total of 68 patients with a median age of 43 years, including children up to 10 months.

The types of disease that were investigated included acute myeloid leukemia (82%), acute lymphocytic leukemia (16%), acute leukemia of mixed phenotype (2%). Among the included patients, 67.6% had KMT2A mutations, 20.6% had NPM1 mutations, and 11.8% had other genotypes.

Patients received intensive pretreatment with a median of four prior lines of therapy and 46% had a prior allogeneic stem cell transplant. The mean response duration was 9 months and the median overall survival was 7 months. Thus, 12 patients underwent allogeneic stem cell transplantation with a response to revumenib.

These early data demonstrate the safety and clinical activity of menin inhibition, known as treatment-induced, in acute leukemia.and the data demonstrate the potential to target cancer cells that have been shown to be specific vulnerable points in cancers.

The researcher explained that targeting menin disrupts the gene transcription machinery and changes gene expression in cancer cells from a leukemia pattern to a normal pattern, ultimately leading to remission.

“The responses in this trial show that menin inhibitors are a promising treatment option that can be well tolerated by patients and could be the most recent addition to successfully targeted therapies for acute leukemia. I look forward to the additional data from these and future trials that will inform the ability to offer this specialized treatment to patients.”

Enrollment for the Phase II Cohort Trial is ongoing. Future trials of revumenib will test combinations with other agents in various settings, newly diagnosed leukemias, relapsed or refractory diseases, and maintenance therapy, for leukemias with KMT2A mutation or NPM1 mutation, and other leukemias in the inhibition of menin mal.

*With information from the European Press.